首页 / 院系成果 / 成果详情页

Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection 期刊论文

编号：

1eb26fe0-8ffd-40c0-9dea-19924bb8de38
作者：

Xiao, Hong(肖宏)#^[1]Chen, Jun^[1];Wang, Jiangrong(王江蓉)^[1]Li, Juhua^[1];Yang, Feia^[1];Lu, Hongzhou(卢洪洲)*^[1]
语种：

英文
期刊：

MEDICINE ISSN：0025-7974 2019 年 98 卷 30 期 ; JUL
收录：
关键词：

co-infection direct-acting antiviral HCV hemophilia HIV
摘要：

Anti-hepatitis C virus (HCV) treatment for human immunodeficiency virus (HIV)/HCV co-positive patients with hemophilia A presents numerous problems in terms of safety and effectiveness. The emergence of direct-acting antiviral (DAA) regimens has led to tremendous changes in the management of HIV/HCV co-infection over the past few years, but the application of DAA in patients with hemophilia complicated with HIV/HCV co-infection has rarely been reported.
We retrospectively analyzed the clinical course and outcome of hemophilia A patients with HIV/HCV co-infection receiving DAA with a focus on the virological response, changes in cluster of differentiation 4 lymphocyte (CD4) count, side effects, and impact on bleeding before and after DAA therapy.
A total of 12 hemophilia A patients with HIV/HCV co-infection were included, 9 of which were severe. All the patients were in stable states with CD4 counts >200/mm(3) and plasma HIV ribonucleic acid (RNA) suppressed (<40IU/mL) while taking the antiretroviral regimen. Majority of the patients (n = 9, 75.0%) were infected with HCV genotype (GT) 1b, while 2 and 1 was infected with HCV GT 2i and HCV GT 3, respectively.
After 12 weeks of DAA treatment, 11 patients (91.7%) obtained sustained virologic response within 24 weeks of discontinuation of treatment (SVR24), except 1 patient who was treated with sofosbuvir (SOF) + pegylated interferon + ribavirin (PR), which was then switched to daclatasvir (DCV) + asunaprevir (ASV) for 12 weeks; this patient then achieved SVR24. During DAA treatment, HIV RNA in all the patients was constantly suppressed, while CD4 counts showed no obvious change.
The most common treatment-emergent adverse events were weakness and loss of appetite (generally mild). There was no evidence of an increased tendency of bleeding, and changes in response to replacement.
DAA therapy offered a safe and well-tolerated management strategy for HIV/HCV co-infected patients with hemophilia A. An awareness of the potential drug-drug interactions (DDI) between DAA and combination antiretroviral therapy (cART) by clinicians is important for optimal management of co-infected patients.
推荐引用方式
GB/T 7714：

Xiao Hong,Chen Jun,Wang Jiangrong, et al. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection [J].MEDICINE,2019,98(30).
APA：

Xiao Hong,Chen Jun,Wang Jiangrong,Li Juhua,&Lu Hongzhou.(2019).Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection .MEDICINE,98(30).
MLA：

Xiao Hong, et al. "Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection" .MEDICINE 98,30(2019).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：30  下载次数：0

分享到：

浏览次数：30

下载次数：0

打印次数：0